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Abstract The enhanced risk of development of lymphopro-
liferative disorders in patients with inflammatory bowel
disease has been attributed to immunosuppressive/immuno-
modulatory therapies. Infliximab is a chimeric monoclonal
immunoglobulin G1 antibody directed against tumor necro-
sis factor alpha (TNF-α) that was approved by the Food and
Drug Administration (FDA) in 1998 as an effective
therapeutic agent against inflammatory bowel disease.
Malignant lymphomas of both B and T cell lineage have
been described in patients undergoing therapy involving
TNF-α blockade. To date, eight cases of Epstein–Barr virus
(EBV)-negative hepatosplenic T cell lymphoma associated
with infliximab have been reported to the FDA’s Adverse
Event Reporting System, as well as several other T cell
lymphoproliferative disorders with aggressive clinical out-
comes. We present the histologic, immunophenotypic, and
molecular features of a T cell lymphoproliferative disorder
involving the axillary lymph node of a 33-year-old male
following infliximab treatment for ulcerative colitis. These
EBV-negative lymphomas suggest that lymphoproliferative
disorders following infliximab treatment for inflammatory
bowel disease may involve EBV-independent immune
dysregulation. The spectrum of lymphoproliferative disor-
ders associated with infliximab and the potential mecha-
nisms by which they occur are discussed.
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Introduction
There is an increased risk of development of lymphopro-
liferative disorders in patients with inflammatory bowel
disease, represented by both ulcerative colitis and Crohn’s
disease. This increased risk may be due to altered lymphoid
proliferation, immunologic defects, and ongoing chronic
inflammation seen in patients suffering from inflammatory
bowel disease. Most of the cases of lymphomas which have
been described in inflammatory bowel disease patients have
been non-Hodgkin lymphomas, although several cases of
Hodgkin lymphoma have also been described. The emer-
gence of a neoplastic clone within long-standing chronic
inflammation may contribute to this predisposition to
lymphoma [1].
Many of the approved therapeutics for inflammatory
bowel disease involve immune modulation through immu-
nosuppressive agents. Immunosuppressive agents such as
azathioprine and mercaptopurines are associated with an
increase in the relative risk of lymphoma development [2–
4]. Many of these lymphomas are positive for Epstein–Barr
virus RNA.
More recently, biologic therapeutic agents such as
infliximab, which is a tumor necrosis factor alpha (TNF-
α) receptor blocker, have become increasingly utilized in
the treatment of inflammatory bowel disease. These agents
work by decreasing T-cell-mediated effects of the immune
system [5–7]. Recent literature has begun to suggest a
correlation with the use of these agents with the develop-
ment of malignant lymphomas. Currently, the US Food and
Drug Administration’s (FDA) Adverse Event Reporting
system has received reports of eight hepatosplenic T cell
lymphomas (HSTCL) in patients treated with infliximab for
inflammatory bowel disease [8], suggesting a mechanism
causing these lymphomas which is distinct from the
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inflammatory bowel disease patients receiving immunosup-
pressive therapy such as steroids, azathioprine, and mer-
captopurines. In this report, we describe the morphologic,
immunophenotypic, and molecular features of an EBV-
negative peripheral T cell lymphoproliferative disorder seen
in a patient treated with infliximab for ulcerative colitis.
Materials and methods
Histologic and immunophenotypic studies
The morphologic features of the case were assessed on
formalin fixed paraffin-embedded tissue sectioned into
hematoxylin-and-eosin-stained slides. Immunohistochemi-
cal studies were performed using an avidin–biotin–perox-
idase complex method and an automated immunostainer
(Ventana-Biotech, Tucson, AZ, USA). The following
immunostains were performed: CD2, CD3, CD4, CD5,
CD7, CD8, CD15, CD20, CD21, CD30, CD56, fascin,
Alk-1, TIA-1, and beta F1. Appropriate positive and
negative controls were used for all immunohistochemical
studies. The sources of antibodies used are as follows: anti-
CD2 (Novocastra, Norwell, MA, USA), anti-CD3 (Ventana,
Tucson, AZ, USA), anti-CD4 (Novocastra), anti-CD5
(Novocastra), anti-CD7 (Novocastra), anti-CD8 (Novocastra),
anti-CD15 (Becton Dickinson, San Jose, CA, USA), anti-
CD20 (Ventana), anti-CD21 (Dako, Carpenteria, CA), anti-
CD30 (Dako), anti-CD56 (Accurate, Westbury, NY, USA),
fascin (Dako), ALK-1 (Dako), TIA-1 (Biocare Medical,
Concord, CA, USA), and beta-F1 (Endogen, Rockford, IL,
USA).
Molecular studies
In situ hybridization
In situ hybridization for EBV was performed as previously
described [9]. An automated in situ hybridization instru-
ment was used to perform the hybridization. EBER-1, an
EBV-encoded digoxigenin-labeled RNA riboprobe, was
diluted in a 50% formamide-containing buffer and applied
to the tissue sections and to appropriate positive and
negative controls. An antisense riboprobe directed against
a small nuclear ribonucleoprotein was used to confirm
RNA integrity of the tissue sections.
PCR analysis
Polymerase chain reaction analysis for clonal rearrange-
ments of the T cell receptor gamma chain gene was
performed as previously described [9].
Results
Clinical history
The patient is a 33-year-old man who was diagnosed with
ulcerative colitis based on colonic biopsies. He was
subsequently treated with the tumor necrosis factor alpha
blocker infliximab. He presented with an acute complaint of
abdominal pain. Computed tomography scan of the
abdomen and pelvis revealed retroperitoneal and mesenteric
abdominal and pelvic lymph node enlargement as well as
splenomegaly. Laboratory workup revealed the patient to be
Fig. 1 Morphologic features of the T cell lymphoproliferative
disorder in an axillary lymph node. a Effacement of lymph node
architecture by a diffuse infiltrate of atypical lymphoid cells.
b Atypical intermediate- to large-sized cells with irregular nuclear
contours and variable prominent nucleoli
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Epstein–Barr virus immunoglobulin G (IgG) and IgM, HIV
antibody, and hepatitis A,B,and C serology. Hesubsequently
underwent an axillary lymph node biopsy for histologic
evaluation of generalized lymphadenopathy.
Light microscopy
Hematoxylin-and-eosin-stained sections from the axillary
lymph node biopsy revealed an infiltrate of atypical
lymphoid cells effacing normal nodal architecture
(Fig. 1a). The infiltrate consisted of intermediate- to large-
sized cells with marked cytologic atypia including irregular
nuclear contours, prominent nucleoli, numerous mitosis,
and areas of karyorrhectic debris (Fig. 1b).
Immunophenotyping
Immunohistochemical stains performed on the paraffin-
embedded tissue showed the atypical cells to be CD3-
positive T cells (Fig. 2a) with expression of CD5, CD4, and
betaF1. Although most of the atypical cells were CD8
negative, a small subset was CD8 positive. The atypical T
cells showed aberrant downregulation of both CD2
(Fig. 2b) and CD7 (Fig. 2c). CD20 and CD79a showed
residual follicular B cells which were overrun by the
neoplastic T cells; however, the large atypical cells were
negative for both B cell markers. CD30 showed moderate
expression, while CD15 and fascin were negative in the
tumor cells. CD21 highlighted residual intact germinal
centers. CD56, ALK-1, and TIA-1 were all negative.
Molecular studies
In situ hybridization for the EBER-1 probe was negative
in the tumor cells (data not shown). T cell receptor
gamma gene rearrangement analysis by polymerase chain
reaction revealed a polyclonal T cell population (data not
shown).
Discussion
Patients with inflammatory bowel disease are at an
increased risk of developing malignant lymphoma indepen-
dent of the use of immunosuppressive agents in their
treatment, which is estimated to be not more than two times
that of a normal individual [10]. Subtypes of malignant
lymphoma that have been described in patients with
inflammatory bowel disease who have not been treated
with immunomodulatory therapy include high-grade B cell
non-Hodgkin lymphomas, “granulomatous” T cell lympho-
ma, Hodgkin lymphoma, and several markedly poly-
morphic lymphomas that were unable to be further
phenotyped [11, 12].
The use of immunosuppressive agents for the treatment
of inflammatory bowel disease increases the risk of
Fig. 2 Immunohistochemical features of the T cell lymphoprolifer-
ative disorder. a Atypical cells show diffuse reactivity to CD3. b
Aberrant loss of CD2 expression. c Aberrant loss of CD7 expression
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and 6-mercaptopurine for the treatment of inflammatory
bowel disease began to increase in the 1990s [13]. Subtypes
of lymphoma described in these immunosuppressed inflam-
matory bowel disease patients include diffuse large B cell
lymphomas, marginal zone lymphomas, Hodgkin lympho-
ma, and plasmacytoma [13]. Seven of 18 azathioprine/6-
mercaptopurine-associated lymphomas were positive for
the Epstein–Barr virus (EBV) in one series [13].
The overall increase in EBV-positive lymphomas, which
are the hallmark of immunosuppression-associated lympho-
mas, in patients treated with azathioprine and 6-
mercaptopurine suggests a common pathogenesis. More
than 80% of non-Hodgkin lymphomas occurring in
transplant recipients are associated with EBV [14]. It is
felt that these lymphoproliferative disorders develop due to
a decreased cell-mediated immune surveillance, which in
turn results in proliferation of EBV-infected B lymphocytes
[15]. Studies evaluating the relative risk of developing
lymphoma while undergoing treatment with azathioprine or
6-mercaptopurines show it to range between slightly greater
than one to up to 60 [12].
The introduction of new biologic agents specifically
designed to target cytokines involved in immune dysregu-
lation has led to new questions about the link between
lymphoma and inflammatory bowel disease. This includes
infliximab, a TNF-α blocker approved by the FDA in 1998.
TNF-α is thought to be a key cytokine involved in the
autoinflammatory mechanism of inflammatory bowel dis-
ease [16]. Infliximab is a chimeric immunoglobulin G1
monoclonal antibody directed against TNF-α, which binds
TNF-α and blocks its interaction with cell surface recep-
tors. In 1998, infliximab became the first “biological
therapy” approved by the FDA for the treatment of adults
with moderate to severe Crohn’s disease unresponsive to
conventional therapy. It was then approved for the pediatric
population for the same indication in May 2006, followed
by approval for the use in adults with moderate to severe
ulcerative colitis in October 2006 [8]. Infliximab has also
been used in treating other immune-mediated diseases, such
as rheumatoid arthritis and psoriatic arthritis. Now, almost
10 years after the introduction of this novel drug into the
treatment of inflammatory bowel disease, data have begun
to show an association between infliximab and malignant
lymphoma.
Large population-based studies report the incidence of
non-Hodgkin lymphoma in patients receiving infliximab for
Crohn’s disease range from 0.2% [17] to 1.4% [18]. A
review of the adverse event surveillance system run by the
FDA published in 2002 found 26 cases of lymphoprolifer-
ative disorders following treatment with anti-TNF-α agents
in the first two and a half years following the introduction
Table 1 Summary of EBV-negative lymphomas associated with anti-tumor necrosis factor alpha therapy
Patient no.
[reference]
Age, year/sex
(indication for use)
TNF-α blocker duration
of use before onset
Tumor subtype Involved sites Outcome/time to death
after diagnosis (if
applicable)
1[ 8] 31/M (CD) 3 years HSTCL Not reported Death/12 months
2[ 8] 15/M (CD) 16 months HSTCL Not reported Death/5 days
3[ 8] 12/M (CD) 58 months HSTCL Not reported Alive
4[ 8] 17/F (CD) 29 months HSTCL Not reported Death/3 months
5[ 8] 19/M (CD) 36 months HSTCL Not reported Death/10.5 months
6[ 8] 18/M (CD) 7 months HSTCL Not reported Death/12 months
7[ 8] 19/M (CD) 2 months (lymphoma
developed 31 months later)
HSTCL Not reported Death/8 months
8[ 8] 22/M (UC) 1 dose only (lymphoma
developed 56 months later)
HSTCL Not reported Alive
9[ 20] 69/M (psoriatic
arthritis)
18 months Sezary syndrome Cutaneous Death/3 months
10 [20] 81/F (CD) 4 months Systemic ALCL Cutaneous/
bone marrow
Death/2 weeks
11 [22] 75/M (ankylosing
spondylitis)
17 months Sezary syndrome Cutaneous Regression with
discontinuation of
infliximab
12 [20] 47/M (psoriasis) 4 doses (lymphoma developed
4 months later)
CD30+T cell lymphoma Cutaneous In remission
13 [this case] 30/M (UC) Unknown Peripheral T cell
lymphoproliferative
disorder
Axillary lymph node Unknown
CD Crohn’s disease, ALCL anaplastic large cell lymphoma, HSTCL hepatosplenic T cell lymphoma, UC ulcerative colitis
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age from 29 to 84 years; the time from first infliximab dose
to lymphoma diagnosis ranged from 2 to 52 weeks. The
subtypes of lymphoma described in this initial report
include diffuse large B cell lymphoma, follicular lympho-
ma, large cell non-Hodgkin lymphoma, small T cell
lymphoma, mantle cell lymphoma, Hodgkin lymphoma,
Burkitt lymphoma, and small lymphocytic B cell lympho-
ma. Notably, two of the cases regressed following the
discontinuation of the anti-TNF-α therapy without cytotox-
ic therapy directed at the lymphoma. One case was EBV
positive, one EBV negative, and the EBV status of the
remaining 24 cases was not reported.
More recently, data have been published regarding the
development of EBV-negative T cell lymphomas in patients
treated with infliximab. HSTCL is a rare aggressive
lymphoproliferative disorder comprising about 5% of
peripheral T cell lymphomas. Of the more than 100 cases
of HSTCL reported in the literature, eight of these cases
were reported to the FDA’s Adverse Event Reporting
System as associated with infliximab use in patients with
ages ranging from 12 to 31 years old being treated for
inflammatory bowel disease [8]. In all cases, the lymphoma
followed an aggressive course, with six patients dead of
disease within 12 months. Other T cell lymphoproliferative
disorders in patients receiving infliximab therapy include
four cases of aggressive cutaneous T cell lymphomas [20–
22], as well as a case of CD30+ T cell lymphoma which
was EBV negative [23]. Table 1 summarizes the cases of
TNF-α-blocker-related T cell lymphomas.
The index case represents an additional case of an EBV-
negative T cell lymphoproliferative disorder in a young
patient following treatment with infliximab for inflamma-
tory bowel disease. Although T cell gene rearrangement
studies did not identify a clonal rearrangement, the aberrant
decreased expression of T cell antigens such as CD2 and
CD7 in the neoplastic Tcells strongly supports the presence
of a T cell neoplastic population. Neither TNF-α nor
infliximab itself has any direct effect on the apoptosis of B
lymphocytes or EBV-positive cell lines, making these T cell
lymphoproliferative disorders less likely to be related to a
direct effect on B cells. Rather this suggests they are related
to an impaired immune surveillance by T cells [5]. Data
also show that infliximab significantly increases the
percentage of CD19-positive cells while decreasing the
percentage of CD3-, CD4-, CD8-, and HLA-DR-positive
(activated) T cells in peripheral blood by inducing T cell
apoptosis, resulting in a decrease in the number of activated
T cells in the inflamed intestinal mucosa of inflammatory
bowel disease patients [6, 7]. Perhaps in blocking the
tumor-necrosis-factor-alpha-mediated apoptosis of circulat-
ing T lymphocytes, infliximab allows for the unrestricted
growth of existing lymphoma cells [20].
CD4-positive T lymphocytes can be divided into two
subtypes: Th1 cells and Th2 cells. Th1 cells secrete
interferon and are involved in cell-mediated immunity
while Th2 cells secrete other cytokines such as interleukin
(IL)-4, IL-5, IL-10, and transforming growth factor beta
and are involved in humoral immunity [24]. Autoimmune
disease is often associated with the activation of Th1 cells.
Th1 cytokines are involved in the inflammatory dysregula-
tion seen in disorders such as inflammatory bowel disease,
rheumatoid arthritis, and psoriasis, while Th2 cytokines
predominate in some lymphomas [20]. Membrane-bound
tumor necrosis factor alpha is present primarily on Th1
lymphocytes. Therefore, blockage and subsequent apopto-
sis of Th1 cells causing autoimmune disease may allow
existing Th2 lymphoma cells to proliferate unchecked [7].
We can hypothesize that T cell lymphomas associated with
infliximab are of the Th2 phenotype.
The apoptosis induced by tumor necrosis factor alpha
blockers of Th1 T lymphocytes may prove to be the
mechanism responsible for the development of T cell
lymphoproliferative disorders in inflammatory bowel dis-
ease. This drug-mediated apoptosis may allow unchecked
proliferation of Th2 T lymphocytes, leading to the
development of malignant lymphoma.
Inflammatory bowel disease is an independent risk factor
for the development of multiple types of malignant
lymphoma. Therapeutic agents that suppress the immune
system are associated with EBV-positive B cell lymphoma
whereas immunomodulatory agents such as infliximab are
associated with EBV-negative T cell lymphoma. Selective
Th1 apoptosis induced by infliximab may be implicated in
the pathogenesis of these lymphomas. Continued study is
needed to further identify a more precise mechanism for the
development of lymphoproliferative disorders in inflamma-
tory bowel disease treated with TNF-α blockade. The FDA
is currently beginning to probe the association of these
drugs with the development of lymphomas [25]. With these
medications being approved for use in more and more
immune-related disorders, clinicians need to keep aware of
this often aggressive consequence of treatment.
References
1. Kumar S, Fend F, Quintanilla-Martinez L et al (2000) Epstein–
Barr virus-positive primary gastrointestinal Hodgkin’s disease.
Am J Surg Path 24:66–73
2. Bouhnik Y, Lemann M, Mary J et al (1996) Long-term follow-up
of patients with Crohn’s disease treated with azathioprine or 6-
mercaptopurine. Lancet 347:215–219
3. Kinlen L (1985) Incidence of cancer in rheumatoid arthritis and
other disorders after immunosuppressive treatment. Am J Med
78:44–49
4. Thayu M, Markowitz JE, Mamula P et al (2005) Hepatosplenic T-
cell lymphoma in an adolescent patient after immunomodulator
J Hematopathol (2009) 2:121–126 125and biologic therapy for Crohn’s disease. J Ped Gastroenterol Nutr
40:220–222
5. Baran-Marszak F, Laguillier C, Youlyouz I et al (2006) Effect of
tumor necrosis factor alpha and infliximab on apoptosis of B
lymphocytes infected or not with Epstein–Barr virus. Cytokine
33:337–345
6. Ferkolj I, Ihan A, Markovic S et al (2006) Infliximab reduces the
number of activated mucosal lymphocytes in patients with
Crohn’s disease. J Gastrointestin Liver Dis 15:231–235
7. Baert FJ, D’Haens GR, Peeters M et al (1999) Tumor necrosis factor
alpha antibody (infliximab) therapy profoundly downregulates the
inflammation in Crohn’s ileocolitis. Gastroenterology 116:22–28
8. Mackey AC, Green L, Liang L et al (2007) Hepatosplenic T cell
lymphoma associated withinfliximabuse inyoungpatients treatedfor
inflammatory bowel disease. J Ped Gastroenterol Nutr 44:265–267
9. Lundell R, Elenitoba-Johnson KSJ, Lim M (2004) Posttransplant
lymphoproliferative disorder occurring in a pediatric solid-organ
transplant patient. Am J Surg Pathol 28:967–973
10. Podolsky D, Gilberto Gonzalez R, Hasserjian R (2006) Case 8-
2006: a 71-year-old woman with Crohn’s disease and altered
mental status. N Engl J Med 354:1178–1184
11. Shepard NA, Hall PA, Williams GT et al (1989) Primary
malignant lymphoma of the large intestine complicating chronic
inflammatory bowel disease. Histopathology 15:325–337
12. Greenstein A, Mullin G, Strauchen J et al (1992) Lymphoma in
inflammatory bowel disease. Cancer 69:1119–1123
13. Dayharsh GA, Loftus EV, Sandborn WJ et al (2002) Epstien–Barr
virus-positive lymphoma in patients with inflammatory bowel
disease treated with azathioprine or 6-mercaptopurine. Gastroen-
terology 122:72–77
14. Reijasse D, Le Pendeven C, Cosnes J et al (2004) Epstein–Barr
virus viral load in Crohn’s disease: effect of immunosuppressive
therapy. Inflamm Bowel Dis 10:85–90
15. Hanto DW, Frizzera G, Purtilo DT et al (1981) Clinical spectrum
of lymphoproliferative disorders in renal transplant recipients and
evidence of the role of Epstein–Barr virus. Cancer Res 41:4253–
4261
16. Rosh JR, Olivia-Hemker M (2006) Infliximab use and hepatos-
plenic T-cell lymphoma: questions to be asked and lessons
learned. J Ped Gastroenterol Nutr 44:165–167
17. Colombel JF, Loftus EV, Tremaine WJ (2004) The safety profile
of infliximab in patients with Crohn’s disease: the Mayo Clinic
experience in 500 patients. Gastroenterology 126:19–31
18. Ljung T, Karlen P, Schmidt D (2004) Infliximab in inflammatory
bowel disease: clinical outcome in a population based cohort from
Stockholm Count. Gut 53:849–853
19. Brown SL, Greene MH, Gershon SK et al (2002) Tumor necrosis
factor antagonist therapy and lymphoma development: twenty-six
cases reported to the food and drug administration. Arthritis
Rheum 46:3151–3158
20. Adams AE, Zwicker J, Curiel C et al (2004) Aggressive cutaneous
T-cell lymphomas after TNFα blockade. J Am Acad Dermatol
51:660–662
21. Berthelot C, Cather J, Jones D et al (2006) Atypical CD8+
cutaneous T-cell lymphoma after immunomodulatory therapy.
Clin Lymphoma Myeloma 6:329–332
22. Dauendorffer JN, Rivet J, Allard A et al (2007) Sezary syndrome
in a patient receiving infliximab for ankylosing spondylitis. Br J
Dermatol 156:742–743
23. Mahe E, Descamps V, Grossin M et al (2003) CD30+T-cell
lymphoma in a patient with psoriasis treated with cyclosporine
and infliximab. Br J Dermatol 149:170–173
24. Janeway CA, Travers P, Walport M, Shlomichik M (2001)
Immunobiology. Garland Publishing, New York
25. Hugget B (2008) FDA probes TNF blockers. Nat Biotechnol
26:845
126 J Hematopathol (2009) 2:121–126